The global cost of nonoptimal blood pressure

Journal of Hypertension

Volumn 27, Issue 7, 2009, Pages 1472-1477

  Gaziano, Thomas A ^a,b   Bitton, Asaf ^c   Anand, Shuchi ^c   Weinstein, Milton C ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Blood pressure; Cost; Global health; Hypertension

Indexed keywords

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR RISK; CONTROLLED STUDY; COST OF ILLNESS; ECONOMIC ASPECT; FEMALE; HEALTH CARE COST; HEART INFARCTION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MALE; PRIORITY JOURNAL; STROKE; SYSTOLIC BLOOD PRESSURE; WORLD HEALTH ORGANIZATION;

EID: 67649755201     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32832a9ba3     Document Type: Article

References (19)

1. Lopez A, Mathers C, EzzatiM, Jamison, Murray C. Global burden of disease and risk factors. Washington, DC: Oxford University Press and World Bank; 2006.
2. Lawes CM, Vander Hoorn S, Rodgers A. Global burden of blood-pressurerelated disease, 2001. Lancet 2008; 371:1513-1518.
3. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. The Lancet 2002; 360:1903-1913.
4. Gaziano TA. Cardiovascular disease in the developing world and its costeffective management. Circulation 2005; 112:3547-3553.
5. Gaziano TA, Steyn K, Cohen DJ, Weinstein MC, Opie LH. Costeffectiveness analysis of hypertension guidelines in South Africa: absolute risk versus blood pressure level. Circulation 2005; 112:3569-3576.
6. DCPP Secretariat. Disease Control Priorities Project: Guidelines for authors. Bethesda, MD: Disease Control Priorities Project, Fogarty International Center, National Institutes of Health; 2004.
7. Ezzati M, Vander Hoorn S, Lopez AD, Danei GRA, Mathers CD. Comparative quantification of mortality and burden of disease attributable to selected risk factors. In: Lopez AD, Ezzati M, Jamieson DT, Murray CJ, editors. Global burden of disease and risk factors. New York: Oxford University Press; 2006. pp. 241-396.
8. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030 diabetes care. 2004; 27:1047-1053.
9. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet2002; 360:1903-1913.
10. McFayden JE, editor. International drug price indicator guide-2005 edition.Boston: Management Sciences for Health; 2006. Pp A1-102.
11. Mulligan J, Fox-Rushby J, Adam T, Johns B, Mills A. Unit costs of healthcare inputs in low and middle income regions. Disease Control Priority Project Working Paper 9, World Bank, Washington, DC. 2003. pp. 1-50.
12. Jones-Lee MW. Safety and the saving of life: the economics of safety and physical risk. In: Layard R, Glaister S, editors. Cost-benefit analysis. Cambridge: Cambridge University Press; 1994. pp. 290-318.
13. World Health Organization. Preventing chronic diseases: a vital investment. WHO Global Report. Geneva: WHO; 2005. pp. 74-87.
14. American Heart Association. Heart Disease and Stroke Statistics - 2004 Update. 2003 [cited July 13, 2003]; Available from: http:// www.americanheart. org.
15. Hodgson TA, Cai L. Medical care expenditures for hypertension, its complications, and its comorbidities. Medical Care 2001; 39:599-615.
16. Murray CJL, Lauer J, Hutubessy R, Niessen L, Tomijima N, Rodgers A, et al.Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk. The Lancet 2003; 361:717-725.
17. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003; 326:1427.
18. Gaziano TA, Opie LH, Weinstein MC. Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis. Lancet 2006; 368:679-686.
19. van den Hoogen PC, Feskens EJ, Nagelkerke NJ, Menotti A, Nissinen A, Kromhout D. The relation between blood pressure and mortality due to coronary heart disease among men in different parts of the world. Seven Countries Study Research Group. N Engl J Med 2000; 342:1-8.